Sector News

Vertex appoints Tom Graney as SVP and CFO

September 8, 2017
Life sciences

Vertex Pharmaceuticals Incorporated has announced the appointment of Tom Graney to the role of Senior Vice President and Chief Financial Officer (CFO).

Mr. Graney will begin his role with Vertex on September 13, 2017 and will report to Executive Vice President and Chief Operating Officer Ian Smith. Mr. Graney will be responsible for the development and execution of the financial strategy and operations that support Vertex’s business plans, including the Finance, Accounting and Internal Audit functions. Mr. Graney most recently served as CFO and Senior Vice President of Finance and Corporate Strategy at Ironwood Pharmaceuticals.

“As Vertex continues its evolution to a leading global biotech, it is critical that we continue to build a strong and experienced leadership team,” said Ian Smith, Executive Vice President and Chief Operating Officer of Vertex. “Tom has the ideal blend of financial acumen, leadership skills, and industry experience that will be important as Vertex grows and expands as a global company.”

“I am thrilled to take on this important role with Vertex, a company that I have long admired for its unwavering commitment to patients and to discovering, developing and commercializing transformative medicines for people with serious and life-threatening diseases,” said Mr. Graney.

Tom Graney Biography
At Ironwood Pharmaceuticals, Mr. Graney was responsible for Finance, Corporate Strategy, Corporate Development, Quality, Supply Chain, IT, Corporate Communications and Investor Relations. Prior to joining Ironwood in 2014, he worked at Johnson & Johnson for approximately 20 years in both the U.S. and abroad, most recently serving as Worldwide VP of Finance and CFO for Ethicon Surgical Care.

Mr. Graney serves on the board of directors of AC Immune SA, a clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases. He holds a B.S. in accounting from the University of Delaware and an M.B.A. in marketing, finance and international business from the Leonard N. Stern School of Business at New York University.

Source: Vertex

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).